Published in Cancer Weekly, June 24th, 2003
Half of all patients saw their disease stabilize or improve.
Median survival time for the advanced-stage patients treated with the combination therapy was 8.6 months, with approximately a third of the 329 patients in the study alive after 1 year.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.